article Open AccessTop 1% cited
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Annals of the Rheumatic Diseases · 2013 · Vol. 73(3) · pp. 492–509
Josef S Smolen✉(Medical University of Vienna)Robert Landewé(Amsterdam UMC Location University of Amsterdam)Ferdinand C. Breedveld(Leiden University Medical Center)Maya H Buch(University of Leeds)Gerd Burmester(Cal Poly Humboldt)Maxime Dougados(Délégation Paris 5)Paul Emery(University of Leeds)C. Gaujoux-Viala(Université de Nîmes)Laure Gossec(Sorbonne Université)J. Nam(University of Leeds)Sofía Ramiro(Amsterdam UMC Location University of Amsterdam)Kevin Winthrop(Oregon Health & Science University)Maarten de Wit(European League Against Rheumatism)Daniel Aletaha(Medical University of Vienna)Neil Betteridge(European League Against Rheumatism)J. W. J. Bijlsma(University Medical Center Utrecht)Maarten Boers(Amsterdam UMC Location Vrije Universiteit Amsterdam)Frank Buttgereit(Cal Poly Humboldt)Bernard Combe(Université de Montpellier)Maurizio Cutolo(University of Genoa)Nemanja Damjanov(University of Belgrade)Johanna M. W. Hazes(Erasmus MC)Marios Kouloumas(European League Against Rheumatism)Tore K Kvien(Diakonhjemmet Hospital)Xavier Mariette(Université Paris-Sud)Karel Pavelká(Charles University)Piet L. C. M. van Riel(Radboud University Nijmegen)Andrea Rubbert‐Roth(University of Cologne)Marieke Voshaar(European League Against Rheumatism)David L. Scott(King's College School)Tuulikki Sokka‐Isler(Central Finland Health Care District)John B. Wong(Tufts University)Désirée van der Heijde(Leiden University Medical Center)
Rheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical MethodsLymphoma Diagnosis and TreatmentMedicineAbataceptAdalimumabCertolizumab pegolTocilizumabGolimumabInfliximabEtanerceptRheumatoid arthritisAntirheumatic drugs
MeSH terms
AlgorithmsArthritis, RheumatoidBiological ProductsDrug Therapy, CombinationGlucocorticoidsHumansImmunosuppressive AgentsTumor Necrosis Factor-alphaAntirheumatic AgentsEvidence-Based Medicine
Funding
- Amgen
- Celgene
- European League Against Rheumatism
Citations
1,756
FWCI
208.74
field-weighted impact
References
158
Percentile
100%
vs. same field & year
Citations per year
Cited by
Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review
European Journal of Medicinal Chemistry · 2018 · 541 citations
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Annals of the Rheumatic Diseases · 2015 · 1,431 citations
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Annals of the Rheumatic Diseases · 2017 · 1,541 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Annals of the Rheumatic Diseases · 2022 · 1,636 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Annals of the Rheumatic Diseases · 2017 · 5,757 citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Annals of the Rheumatic Diseases · 2020 · 2,709 citations
References
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Arthritis & Rheumatism · 2005 · 1,780 citations
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
Arthritis & Rheumatism · 2004 · 1,165 citations
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Arthritis & Rheumatism · 2006 · 1,050 citations
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Annals of the Rheumatic Diseases · 2009 · 804 citations
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
The Lancet · 2012 · 8,966 citations
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Lara D. Veeken · 2009 · 355 citations
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
The Lancet · 2012 · 8,330 citations
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Annals of the Rheumatic Diseases · 2007 · 740 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.